Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment

Brian Morse; Daniel Jeong; Gary Ihnat; Alvin C. Silva

doi:10.1007/s00261-018-1752-4

Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment

Brian Morse, Daniel Jeong, Gary Ihnat, Alvin C. Silva

Diagnostic Radiology

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Oncologic imaging is an important facet of abdominal imaging that radiologists encounter nearly every day. Many oncology clinical trials utilize response evaluation criteria in solid tumors (RECIST) version 1.1 which divides tumor sites into target and non-target lesions. Although RECIST v1.1 provides clear instructions regarding the use of imaging in clinical trials, errors in response assessment still occur using these criteria. This is especially true of response assessment with regards to non-target lesions which involve rules which are less well-defined and somewhat subjective. This pictorial essay will review RECIST v1.1 guidelines and common non-target lesion errors which can occur at baseline and follow-up response assessment.

Original language	English (US)
Pages (from-to)	766-774
Number of pages	9
Journal	Abdominal Radiology
Volume	44
Issue number	2
DOIs	https://doi.org/10.1007/s00261-018-1752-4
State	Published - Feb 15 2019

Keywords

Non-target lesion
RECIST v1.1
Response assessment
Target lesion

ASJC Scopus subject areas

Radiological and Ultrasound Technology
Radiology Nuclear Medicine and imaging
Gastroenterology
Urology

Access to Document

10.1007/s00261-018-1752-4

Cite this

@article{14d35a7a209942618301f74314a68830,

title = "Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment",

abstract = "Oncologic imaging is an important facet of abdominal imaging that radiologists encounter nearly every day. Many oncology clinical trials utilize response evaluation criteria in solid tumors (RECIST) version 1.1 which divides tumor sites into target and non-target lesions. Although RECIST v1.1 provides clear instructions regarding the use of imaging in clinical trials, errors in response assessment still occur using these criteria. This is especially true of response assessment with regards to non-target lesions which involve rules which are less well-defined and somewhat subjective. This pictorial essay will review RECIST v1.1 guidelines and common non-target lesion errors which can occur at baseline and follow-up response assessment.",

keywords = "Non-target lesion, RECIST v1.1, Response assessment, Target lesion",

author = "Brian Morse and Daniel Jeong and Gary Ihnat and Silva, {Alvin C.}",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2019",

month = feb,

day = "15",

doi = "10.1007/s00261-018-1752-4",

language = "English (US)",

volume = "44",

pages = "766--774",

journal = "Abdominal Radiology",

issn = "2366-004X",

publisher = "Springer New York",

number = "2",

}

TY - JOUR

T1 - Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment

AU - Morse, Brian

AU - Jeong, Daniel

AU - Ihnat, Gary

AU - Silva, Alvin C.

PY - 2019/2/15

Y1 - 2019/2/15

N2 - Oncologic imaging is an important facet of abdominal imaging that radiologists encounter nearly every day. Many oncology clinical trials utilize response evaluation criteria in solid tumors (RECIST) version 1.1 which divides tumor sites into target and non-target lesions. Although RECIST v1.1 provides clear instructions regarding the use of imaging in clinical trials, errors in response assessment still occur using these criteria. This is especially true of response assessment with regards to non-target lesions which involve rules which are less well-defined and somewhat subjective. This pictorial essay will review RECIST v1.1 guidelines and common non-target lesion errors which can occur at baseline and follow-up response assessment.

AB - Oncologic imaging is an important facet of abdominal imaging that radiologists encounter nearly every day. Many oncology clinical trials utilize response evaluation criteria in solid tumors (RECIST) version 1.1 which divides tumor sites into target and non-target lesions. Although RECIST v1.1 provides clear instructions regarding the use of imaging in clinical trials, errors in response assessment still occur using these criteria. This is especially true of response assessment with regards to non-target lesions which involve rules which are less well-defined and somewhat subjective. This pictorial essay will review RECIST v1.1 guidelines and common non-target lesion errors which can occur at baseline and follow-up response assessment.

KW - Non-target lesion

KW - RECIST v1.1

KW - Response assessment

KW - Target lesion

UR - http://www.scopus.com/inward/record.url?scp=85053323384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053323384&partnerID=8YFLogxK

U2 - 10.1007/s00261-018-1752-4

DO - 10.1007/s00261-018-1752-4

M3 - Review article

C2 - 30196362

AN - SCOPUS:85053323384

SN - 2366-004X

VL - 44

SP - 766

EP - 774

JO - Abdominal Radiology

JF - Abdominal Radiology

IS - 2

ER -

Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this